​

Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

ForecastOwnershipFinancialsChartTranscripts
Acumen Pharmaceuticals by TradingView

Previous Close

$2.24

52W Range

$1.05 - $3.60

50D Avg

$2.49

200D Avg

$2.21

Market Cap

$143.56M

Avg Vol (3M)

$538.70K

Beta

0.35

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

61

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-123.83M$-114.02M$-61.14M
Net Income$-121.33M$-102.33M$-52.37M
EBITDA$-123.83M$-98.08M$-51.61M
Basic EPS$-2.00$-1.71$-1.08
Diluted EPS$-2.00$-1.71$-1.08

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 26, 26 | 12:00 AM
Q3 25Nov 12, 25 | 8:00 AM
Q2 25Aug 12, 25 | 12:00 AM

Peer Comparison

TickerCompany
ACTUActuate Therapeutics Inc
IRDOpus Genetics, Inc.
ALECAlector, Inc.
SPROSpero Therapeutics, Inc.
AGENAgenus Inc.
SEERSeer, Inc.
INOInovio Pharmaceuticals, Inc.
VTGNVistaGen Therapeutics, Inc.
FATEFate Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.